The role of Cdk5 in neurological disorders

Chuncao Ao¹, Chencheng Li¹, Jinlun Chen¹, Jieqiong Tan²,³,⁴ and Liuwang Zeng¹*

¹Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, China, ²Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China, ³Hunan Key Laboratory of Medical Genetics, Central South University, Changsha, China, ⁴Hunan Key Laboratory of Animal Model for Human Diseases, Central South University, Changsha, China

Neurological disorders are a group of disorders with motor, sensory or cognitive damage, caused by dysfunction of the central or peripheral nervous system. Cyclin-dependent kinases 5 (Cdk5) is of vital significance for the development of the nervous system, including the migration and differentiation of neurons, the formation of synapses, and axon regeneration. However, when the nervous system is subject to pathological stimulation, aberrant activation of Cdk5 will induce abnormal phosphorylation of a variety of substrates, resulting in a cascade signaling pathway, and thus lead to pathological changes. Cdk5 is intimately related to the pathological mechanism of a variety of neurological disorders, such as Aβ protein formation in Alzheimer’s disease, mitochondrial fragmentation in cerebral ischemia, and apoptosis of dopaminergic neurons in Parkinson’s disease. It is worth noting that Cdk5 inhibitors have been reported to have neuroprotective effects by inhibiting related pathological processes. Therefore, in this review, we will briefly introduce the physiological and pathological mechanisms of Cdk5 in the nervous system, focusing on the recent advances of Cdk5 in neurological disorders and the prospect of targeted Cdk5 for the treatment of neurological disorders.

KEYWORDS
cyclin-dependent kinases 5 (Cdk5), neurological disorders, therapeutic targets, CDK5 inhibitor, nervous system

Introduction

Neurological disorders are featured by impairment movement, sensation, cognition, and behavior, which is caused by damage to the peripheral nervous system or central nervous system. These diseases share similar pathophysiological mechanisms, such as oxidative stress, cytotoxicity, mitochondrial fragmentation, autophagy, endoplasmic reticulum stress, neuroinflammation, and calcium overload. However, divergent pathological manifestations exist in the different disorders (Sorensen, 2019). Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase, which is a unique component of the family of cyclin-dependent kinases (Dhavan and Tsai, 2001; Malumbres, 2014). Cdk5 plays a pivotal role in the nervous system, including cortex layer formation, synaptic growth and maturation, synaptic vesicular transport (Liu et al., 2022; Takahashi et al., 2022a), stress-enhanced memory consolidation, dendritic spine formation, neuronal migration and differentiation, neurite outgrowth and length (Chen et al., 2017; Huang et al., 2017; Shinmyo et al., 2017; Lee et al., 2018; Nishino et al., 2019; Rao et al., 2020; Im et al., 2022), learning and long-term behavioral changes, axonal...
regeneration (Xu et al., 2017; Hwang and Namgung, 2021), brain microtubule network and actin cytoskeleton remodeling (Shah and Lahiri, 2017; Shah and Rossie, 2018), as well as normal cerebellar development and functions (Lee et al., 2019; Li et al., 2019; Kodani et al., 2020; Ouyang et al., 2020). Additionally, Cdk5 also plays a key role in gene expression, cell differentiation, angiogenesis, and aging (Arif, 2012).

Cdk5 also plays a key role in the pathological process of neurological diseases. Cdk5 binds to specific partners p35 and p39, after the pathological stimulus. P35 and p39 are cleaved to p25 and p29 by calpain, with the increase in calcium concentration. The association of Cdk5/p25 is more stable and leads to aberrant hyperphosphorylation of substantial Cdk5 substrates, resulting in cell death or apoptosis (Asada et al., 2012; Nie et al., 2022). Cdk5 has also been implicated in the development and progression of a variety of cancers, including breast, lung, colon, pancreatic, melanoma, thyroid, and brain tumors, making it a promising drug target for new anticancer treatments (Pozo and Bibb, 2016).

When Cdk5 inhibitors are given, they show neuroprotective effects on numerous cell and animal models. Cdk5 inhibitors have great potential to be a therapeutic target for neurological system diseases. In this review, we will summarize recent advances in the molecular mechanisms of Cdk5 in neurological diseases as well as the therapeutic potential of Cdk5 in these neurological diseases.

Under normal circumstances, Cdk5 is in an inactive state. After binding to p35, it is normally activated, phosphorylates many substrates, and plays normal physiological functions such as neuron development and development, axonal dendrite growth, and prominent functions. When neurons are pathologically stimulated, the influx of intracellular calcium ions increases, and after combining with calcium, p35 is split into p25. The combination of p25 and CDK5 will cause CDK5 to be in an over-activated state, thereby hyperphosphorylating various substrates in cells, causing abnormal pathophysiological responses, and leading to neurological diseases (Figure 1).

### Neurodegenerative diseases

Cdk5 hyperactivation contributes to several neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD; Cheung and lp, 2012).

#### Alzheimer’s disease (AD)

**Aβ generation**

Aβ protein deposition is not only the pathological feature of AD but also the key factor of AD progression. Aβ is produced through sequential amyloidogenic cleavage of precursor protein APP by β-secretase BACE1 and γ-secretase, with the oligomer form considered to be the toxic form (Mawuenyega et al., 2010). The mechanisms underlying Cdk5 in Aβ generation and neurotoxicity are multifaceted. Cdk5 activation promotes Aβ generation and accumulation in neurons. PPAR-β, a nuclear receptor with a key role in metabolic processes, is a phosphorylated substrate of Cdk5 and involved in Aβ generation (Quan et al., 2019; Ribeiro Filho et al., 2019). Hypoxia leads to abnormal phosphorylation of Cdk5 and accelerates the process of AD (Fang et al., 2019). Cdk5/HIF-1 contributes to Aβ generation (Chao et al., 2020). Cdk5 regulates Aβ-induced mitochondrial fission and neurotoxicity by phosphorylating Drp1 (Guo et al., 2018), which may be mediated by P27 (Jaiswal and Sharma, 2017). APP, GSK-3β, and TrkA play important roles in Aβ pathological process, which is at least partly mediated by Cdk5 activation (Palop and Mucke, 2010). Aβ regulates the activity of Cdk5 as well (Lapresa et al., 2019). Aβ protein physiological aggregation regulates Cdk5/Calcineurin signaling (Lazarevic et al., 2017). Therefore, inhibiting the activity of Cdk5 is of great significance in reducing Aβ generation and delaying the progress of AD. Roscovitine, an inhibitor of Cdk5, effectively reverses Aβ formation. Ginsenoside Rg1 can decrease Aβ level via inhibiting the Cdk5/ PPAR γ pathway (Quan et al., 2020). Some other drugs, such as streptozotocin, ketamine, and phosphocreatine, also decrease Aβ levels through Cdk5 related pathway (Li et al., 2020a; Park et al., 2020; Ai et al., 2022). Therefore, targeting Cdk5 and the related pathways is a potential strategy for AD therapy.

#### Tau phosphorylation

Tau phosphorylation and the formation of neurofibrillary tangles in neurons is one of the notable hallmarks of AD pathology. Aberrant phosphorylation and deposition of tau, which is a cellular microtubule associated protein, will affect the activity of microtubule and destroy cytoskeleton structure, leading to neuronal apoptosis. Tau is a substrate of different kinases, such as Cdk5, GSK-3β, or PKA. Cdk5 plays a key role in tau phosphorylation and neurofibrillary tangles formation (Teo et al., 2017). The miR-148a-3p/p35/PTEN signaling pathway is an important pathway for tau hyperphosphorylation in AD (Zeng et al., 2021). Many factors such as MARK4 (Saito et al., 2019), and RPS23RG1 (Zhao et al., 2021), have been proved to be related to tan pathology through regulating Cdk5 activity. Glutamate induces Cdk5 and p35 mRNA transcription. The glutamate-responsive increase of the Cdk5/p25 complex contributes to tau hyperphosphorylation (Tanaka et al., 2022). Cdk5 is also associated with early inflammation of AD (Wilkaniec et al., 2018). Leukotriene, an inflammatory factor, may accelerate tau pathological accumulation through the Cdk5 pathway (Giannopoulos et al., 2019). Tau affects the function of subcellular organelles, such as mitochondria and
Golgi apparatus, through Cdk5 (Mohamed et al., 2017). Cdk5 inhibitory peptide (CIP) can not only prevent the loss of neurons and alleviate behavioral changes but also reduce tau hyperphosphorylation and inflammation (Xu et al., 2019; Huang et al., 2020). Drugs like Quercetin can inhibit the pathological process of tau through the Ca\(^{2+}\)-calpain-p25-Cdk5 pathway (Shen et al., 2018). For the pivotal role of Cdk5 in tau phosphorylation and the formation of neurofibrillary tangles, Cdk5 is supposed to be a promising therapeutic target for AD.

Cdk5 inhibition in AD

Cdk5 inhibitors can delay the pathological progression of AD and prevent neuronal apoptosis. They have not been put into clinical trials because of poor selectivity. More and more studies continue to try to find new Cdk5 inhibitors and new substrates of Cdk5 (Zhuang et al., 2020b). Recent studies have found some new substrates and signaling pathways related to Cdk5 in AD, such as Cdk5-Mcl-1 axis (Nikhil and Shah, 2017), ALDH1A1 (Nikhil et al., 2019), miR-125b (Zhuang et al., 2020a), and miR-504-3p (Chen et al., 2022). New Cdk5 inhibitors are also being studied in various AD models like pyrrolidine-2,3-dione, and TFP5 (Shukla et al., 2017; Zeb et al., 2019a,b). It is also found that a traditional Chinese medicine, Nano-HO, improves cognitive function in AD by modulating the signaling pathway JNK/cdk5/GSK-3β (Qu et al., 2021). Similarly, Kaixinsan, a traditional Chinese medicine for insomnia, is found to attenuate tau hyperphosphorylation and neuroinflammation by inhibiting GSK3β and CDK5 activation (Jiao et al., 2022). All of these chemicals have shown neuroprotective effect but the specific mechanism is still not fully elucidated.

Parkinson’s disease (PD)

The main pathological change of Parkinson’s disease is the degeneration of substantia nigra pars compacta neurons. However, the mechanism of Lewy body formation is still unclear. Moreover, there is no effective treatment to slow down the process of neurodegeneration (Kalia and Lang, 2015). Dysregulation of Cdk5 is supposed to be related to the loss of dopaminergic neurons and the progression of PD. Aberrant p25/Cdk5 signaling was found in early-stage PD (He et al., 2020). Previous studies found that Cdk5 can promote oxidative stress, and lead to mitochondrial dysfunction and autophagy dysfunction in PD. Moreover, in the mouse model of PD induced by MTPP aberrant Cdk5 results in activation of inflammation (Cheng et al., 2020), immune hyperactivity (Shukla et al., 2019), mitochondrial fission (Park et al., 2019), and degradation of ubiquitin ligases (Wang et al., 2018), leading to the loss of...
dopaminergic neurons. Cdk5 phosphorylation induced nuclear translocation of SIRT2 also leads to the loss of dopaminergic neurons (Yan et al., 2022). Similarly, Cdk5 inhibitors have exerted neuroprotective effects in PD (He et al., 2018). Luteolin was reported to confer neuroprotective effect on the PD model, which was also mediated by Cdk5 (Reudhabibadh et al., 2022).

Huntington’s disease (HD)

Huntington’s disease (HD) is an autosomal dominant disease with a combination of motor, cognitive, and behavioral characteristics. HD is caused by the extended CAG trinucleotide repeat (variable length) in HTT (the gene encoding protein huntingtin; Bates et al., 2015). Huntington protein leads to neuronal dysfunction and death through a variety of mechanisms, including proteinase deposition, destruction of
transcription and mitochondrial function, and direct toxicity of mutant protein (McColgan and Tabrizi, 2018). Cdk5 has been confirmed to participate in the pathological process (Bowles and Jones, 2014). It was suggested that, unlike in AD and PD, Cdk5 exerts neuroprotective effects in HD (Kaminosono et al., 2008). However, some other studies have yielded different results. It was reported that Cdk5 knockout with overexpression of mutated huntingtin (MHTT) alleviated cortical striatal learning deficits and hippocampus dependent memory decline (Alvarez-Periel et al., 2018). P25/Cdk5 signaling is an important mediator of dopamine and glutamate neurotoxicity associated with HD (Paoletti et al., 2008). Cdk5 mediates dopaminergic neurotoxicity by regulating Drp1, which induces mitochondrial fragmentation in HD pathology (Cherubini et al., 2015). In the nucleus accumbens, Cdk5 dysfunction regulates DARPP-32 phosphorylation, which contributes to depression-like behavior in HD (Brito et al., 2019). Therefore, Cdk5 is supposed to get double-sided nature in HD diseases. How to use its beneficial side and how to prevent its detrimental side is a task worthy of consideration in the future (Figure 2).

**Cerebrovascular disease (CVD)**

Cerebrovascular disease is the most common disease in the nervous system and one of the major threats to human health and life worldwide (Langhorne et al., 2011). In recent years, there is evidence that targeting Cdk5 can protect synaptic plasticity and provide long-term neuroprotection after stroke (Gutierrez-Vargas et al., 2017).

**Ischemic stroke**

Cerebral ischemia is one of the most serious public health problems worldwide (Tolonen et al., 2005). The important pathophysiological mechanisms of ischemic stroke are neuroinflammation, oxidative stress, calcium overload, mitochondrial fragmentation, and Golgi stress caused by ischemia and hypoxia (Sun et al., 2019). As a unique Cdk in the nervous system, Cdk5 has been demonstrated to play an important role in the pathological process of ischemic stroke. In a large number of animal models of cerebral ischemia or neuronal cell ischemia models, Zincchelator (Tuo et al., 2018), neuregulin-1 β (Zhang et al., 2018), tfp5 (Ji et al., 2017), and tat-Cdk5 CTM (Zhu et al., 2019) are found to have a neuroprotective effect through Cdk5 related pathways. Cdk5 inhibition with scCdk5mir astrocytes (Becerra-Calixto and Cardona-Gomez, 2017), Cdk5 RNAi-based therapy (Munoz-Manco et al., 2018) or transplanted with PTPN21 (Cui et al., 2017) also confers neuroprotection in ischemic stroke. The mechanisms underlying Cdk5 in ischemia stroke are multifaceted, such as protecting cells through the ERK1/2 signaling pathway (Zhao et al., 2017), inhibition of p53 dependent apoptosis (Shin et al., 2019), trkb-erk1/2-creb pathway (Liu et al., 2017), phosphorylation of drp1S616 (Chen et al., 2021) and sponging miR-148b-3p.
Intracerebral hemorrhage (ICH)

Intracerebral hemorrhage (ICH) is a common cerebrovascular disorder, accompanied by a particularly high mortality. The prognosis of ICH is not satisfying. Thus, it is essential to understand the potential molecular mechanisms of ICH-induced brain injury (Wilson et al., 2015). The most serious damage of cerebral hemorrhage to neurons is due to hematoma compression and hemorrhagic inflammation related pathological changes, while most of the subcellular pathological changes are similar to ischemic stroke. Inhibition of Cdk5 activity, such as knockout of Cdk5 kinase activity (Ke et al., 2015) or glycosylated Cdk5 (Ning et al., 2017), also showed neuroprotective effect in intracerebral hemorrhage. The Cdk5-ATM signaling pathway has been demonstrated to protect neurons in the process of cerebral hemorrhage (Wu et al., 2016). Phosphorylation of p35 also attenuated neuronal apoptosis through Cdk5 (Roufayel and Murshid, 2019). Moreover, p75NTR promoted p33 dephosphorylation and induced neuronal apoptosis after intracerebral hemorrhage (Zhou et al., 2019). Therefore, Cdk5 plays an important role in intracerebral hemorrhage and is a potential therapeutic target.

Neuropathic pain (NP)

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers and central neurons (Bouhassira, 2019). The development of NP is caused by many pathophysiological mechanisms that affect pain pathways (Colloca et al., 2017). As a unique Cdk of the nervous system, Cdk5 has been proved to play an important role in the pathogenesis of NP. The role of Cdk5 in NP and its potential substrates, such as channels, proteins involved in neurotransmitter release, and receptors, were discussed in many studies (Gomez et al., 2020b). Researchers have visualized the regulation of trigeminal sensory neurons by Cdk5, showed the expression change of Cdk5 and the accumulation of calcium ions, and provided a strong basis for revealing the pathological mechanism of neuralgia (Hu et al., 2022). The level of Cdk5 and phosphorylated CRMP2 was increased in NP models, and inhibition of CRMP2 could alleviate NP (Moutal et al., 2019). Cdk5 inhibitors can inhibit neuralgia through the Cdk5-NR2A pathway (Yang et al., 2014) or attenuate the response of TRPA1 (Sulak et al., 2018). Cdk5 also plays a critical role in regulating myelin basic protein (MBP) fragment (Chernov et al., 2018), inflammatory pain (Zhu et al., 2021), and calcium channel (Gomez et al., 2020a, 2021) in NP. Cdk5 mediated cyclic AMP response element binding protein (CREB; Li et al., 2014) and regulated NP through Cdk5/PPARγ pathway (Zhong et al., 2019). Silencing noncoding RNA H19 can relieve by inhibiting Cdk5 mediated phosphorylation of CREB (Li et al., 2020). Based on these findings, Cdk5 is supposed to be a potential target to attenuate neuralgia.

Epilepsy

Epilepsy is a brain disease, with more than 70 million people suffering from epilepsy worldwide (Thijs et al., 2019). The pathophysiological mechanism of epilepsy is not fully clarified. There is a high incidence of comorbidity and premature mortality in patients with epilepsy (Yuen et al., 2018). It is important to understand the molecular mechanism of epilepsy in order to find new prognostic/diagnostic biomarkers. Cdk5 naturally plays an important role in the pathological process of epilepsy. Cdk5 maintains the steady-state synaptic plasticity by regulating the synaptic cascade in neurons. In the animal refractory epilepsy model, the expression of the Cdk5 gene at the transcriptional level has been proved to be abnormal (Dixit et al., 2017). Cdk5 plays different roles in different brain regions in patients with mesial temporal lobe epilepsy with hippocampal sclerosis (Banerjee et al., 2021). The occurrence and development of epilepsy are related to the blood-brain barrier. It is verified that endothelial specific Cdk5 knockout induced spontaneous seizures in mice (Liu et al., 2020). In status epilepticus, Cdk5 promotes neuronal apoptosis through excessive mitochondrial fragmentation (Kim and Kang, 2017), regulates neuroinflammation (Hiragi et al., 2018), and endoplasmic reticulum stress (Lee and Kim, 2021). After status epilepticus, Cdk5 was less expressed in CA1 cells in animal models (Kim and Kang, 2018). Roscovitine, a Cdk5 inhibitor, inhibits status epilepticus-induced neuroinflammation by regulating p38 MAPK-mediated microglial response (Kim et al., 2019). P35 and P39, Cdk5 activators, have also been shown to play a significant role in synaptic function and epileptic response (Li et al., 2016). The change of Cdk5/p35 expression in the hippocampus may play a role in epilepsy by affecting mossy fiber germination (Tian et al., 2008, 2010). It is well known that NMDAR is intimately related to epilepsy. NMDAR induced axon injury in temporal lobe epilepsy through regulating GSK-3β and Cdk5 (Liu et al., 2017; Fan et al., 2020). However, more studies are still needed to unveil the role of Cdk5 in the pathophysiological process of epilepsy.
Molecular mechanisms of Cdk5 in some of the neurological diseases. →: promote or aggravate; ⊣: inhibit or protect.

Glioblastoma

Glioblastoma (GBM) is an aggressive malignant primary brain tumor. Currently, there are only palliative treatments such as radiotherapy and chemotherapy (Stupp et al., 2009). It is important to find effective therapeutic drugs for GBM. The aberrant activity of Cdk5 is found in various tumors, including GBM. A biosensor for Cdk5 can be used to probe Cdk5 activity in living glioblastoma cells by fluorescence imaging (Peyressatre et al., 2020b). The level of Cdk5 may be a potential biomarker for early diagnosis of GBM (Gonzalez-Vera et al., 2016). Cdk5 is also identified as a valuable predictive marker for tumorigenesis and progression in GBM. Cdk5 can promote the migration, invasion, and progression of GBM by phosphorylating PIKE-A (Liu et al., 2008) and Drp1 (Xie et al., 2015). Cdk5 inhibition by TP5 (Tabouret et al., 2020), AC1MYR2 (Ren et al., 2015), inhibition of DYRK1A (Chen et al., 2021), Cdk5 knockdown (Zhou et al., 2021), and a new quinazolinone family (Peyressatre et al., 2020a) can suppress the progression of GBM. Moreover, it is supposed that targeting the Cdk5/TRIM59 signal axis (Sang et al., 2019) and OGT/CDK5/ACSS2 pathway (Ciraku et al., 2022) may be future strategies for the treatment of GBM (Figure 3).

Multiple sclerosis

Cdk5 is essential in regulating the transformation of the precursor cells of adult oligodendrocytes to mature oligodendrocytes (Lao et al., 2014). Cdk5 plays an important role in the formation of myelin sheath for oligodendrocytes. Abnormal Cdk5 activity can lead to demyelination-related diseases, such as multiple sclerosis (Luo et al., 2016). Cdk5 activity in oligodendrocytes contributes to demyelination and cognitive dysfunction in a mouse model of multiple sclerosis (Luo et al., 2018). However, the specific mechanism for Cdk5 in multiple sclerosis is still unclear. It is found that Cdk5 can participate in the pathological process of multiple sclerosis by regulating lymphocyte activation (Pareek et al., 2010).

Other neurological disorders

Cdk5 has been proved to play a key role in many other neurological diseases, such as ALS (Bk et al., 2019), early brain injury (Ding et al., 2022), cerebral amyloidosis (Kiss et al., 2020), fragile X-associated tremor/ataxia syndrome (FXTAS; Robin et al., 2017), spinal muscular atrophy (Tejero et al., 2020), and systemic sclerosis (Wei et al., 2017). Circadian behavior (Zhou et al., 2022), learning disabilities (Kamiki et al., 2018), and aging (Spurrier et al., 2018) are also closely related to Cdk5. Diabetes induces brain damage by regulating Cdk5 phosphorylation (Li et al., 2020b). Inhibition of Cdk5 improves glucose uptake in insulin-resistant neuronal cells via the ERK1/2 pathway (Manglani and Dey, 2022), and alleviates cognitive deficits caused by diabetes (Liu et al., 2019). Inhibition of the Cdk5/caspase-3 pathway by p5-TAT can also attenuate radiation-induced cognitive dysfunction.
FIGURE 4
Pathological mechanisms of Cdk5 in neurological disorders. When neurons are subjected to pathological stimuli, such as ischemia and toxic injury, Cdk5 is highly activated after binding to p25, phosphorylates many substrates, and also induces mitochondrial fragmentation, Golgi apparatus and endoplasmic reticulum dysfunction, and destruction of the cytoskeleton. Cdk5 inhibitors can attenuate or even reverse the above pathological processes.

(Zhang et al., 2021). Inhibition of Cdk5 activity ameliorates anxiety and depression in mice (Takahashi et al., 2022b). Cdk5 is found to induce mitochondrial kinetic defects in optic neuropathy (Rong et al., 2020). Cdk5 phosphorylates CRMP-2, which will aggravate optic nerve damage (Chen et al., 2019). Cdk5 contributes to oxidative stress (Guo et al., 2018) and endoplasmic reticulum stress (Shi et al., 2018). Nestin is closely related to Cdk5 signaling (Lindqvist et al., 2017) and the nestin-Cdk5-drp1 axis regulates neural stem cell stemness (Wang et al., 2018). The role of Cdk5 in nervous system diseases may be different in male and female models (Barrett et al., 2019). Estrogen promotes axon regeneration after subcortical axon injury through the PI3K/Akt/CDK5/Tau pathway (Xia et al., 2020). Epigenetic editing of Cdk5 also has been applied to neurological disorders, such as sex-specific regulation of fear memory (Sase et al., 2019). Till now, researchers try to find new phosphorylation substrates of Cdk5 (Roach et al., 2018), and discover new Cdk5 inhibitors by various biotechnology methods (Shukla and Singh, 2020, 2022). In a recent study, a highly selective inhibitor of CDK5, GFB-12811, was discovered and optimized (Daniels et al., 2022). A brain-penetrating Cdk5 inhibitor was also developed and found to alter neurobehavior (Figure 4; Umfress et al., 2022).

Conclusion

In general, our understanding of Cdk5 in neurological disorders has made great progress in recent years. A large number of studies have confirmed its important physiological function and its toxic effect after over-activation. It is increasingly clear and certain that Cdk5 plays a pivotal role in the physiological function of the nervous system and the pathological process of neurological disorders. Cdk5 inhibitors have shown promising effects in numerous studies and Cdk5 has great potential as a therapeutic target for neurological disorders. However, many issues, such as the more detailed molecular mechanisms of Cdk5 in different neurological disorders and the development of more selective inhibitors of CDK5, still need to be further clarified before its clinical application.
Author contributions

CA and LZ conceived, organized, and discussed the work. CA contributed to manuscript writing and literature search. CL, JC, JT, and LZ revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work has been supported by National Natural Science Foundation of China (Grant no. 81771423 and 81974212) and Natural Science Foundation of Hunan province (Grant no. 2020JJ4822).

References

Ai, J., Wang, H., Chu, P., Shopit, A., Niu, M., Ahmad, N., et al. (2022). The neuroprotective effects of phosphocreatine on amyloid beta 25-35-induced differentiated neuronal cell death through inhibition of AKT/GSK-3β/Tau/APP/CDK5 pathways in vivo and vitro. Free Radiic. Biol. Med. 179, 416–417. doi: 10.1016/j.freeradbiomed.2021.12.306

Alvarez-Periel, E., Pugdollibov, M., Brito, V., Platter, F., Bibb, J. A., Albercher, J., et al. (2018). CDK5 contributes to Huntington’s disease learning and memory deficits via modulation of brain region-specific substrates. Mol. Neurobiol. 55, 6250–6268. doi: 10.1007/s12031-017-0828-4

Arif, A. (2012). Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase CDK5. Biochem. Pharmacol. 84, 985–993. doi: 10.1016/j.bcp.2012.06.027

Asada, A., Saito, T., and Hisanaga, S. (2012). Phosphorylation of p35 and p39 by CDK5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner. J. Cell Sci. 125, 3421–3429. doi: 10.1242/jcs.105053

Banerjee, J., Srivastava, A., Sharma, D., Dey, S., Tripathi, M., Sharma, M. C., et al. (2021). Differential regulation of excitatory synaptic transmission in the hippocampus and anterior temporal lobe by cyclin dependent kinase 5 (Cdck5) in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Neurosci. Lett. 761:136096. doi: 10.1016/j.neulet.2021.136096

Barrett, T., Marchalant, Y., and Park, H. J. K. (2019). p35 hemizygous deletion in SfaFad mice increases Aβ plaque load in males but not in females. Neuroscience 417, 45–56. doi: 10.1016/j.neuroscience.2019.08.017

Bates, G. P., Dorsey, R., Guessa, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., et al. (2015). Huntington disease. J. Neurogenet. Sci. 84, 985–993. doi: 10.1016/j.neuroscience.2019.08.017

Beccara-Calixto, A., and Cardona-Gomez, G. P. (2017). Neuroprotection induced by transplanted CDK5 knockdown astrocytes in global cerebral ischemic rats. Mol. Neurobiol. 54, 6681–6696. doi: 10.1007/s12031-016-0162-2

Beccara-Calixto, A., Posada-Duque, R., and Cardona-Gomez, G. P. (2018). Recovery of neurovascular unit integrity by CDK5-KD astrocyte transplantation in a global cerebral ischemia model. Mol. Neurobiol. 55, 8563–8585. doi: 10.1007/s12031-018-0992-1

Blk, B., Skuntz, S., Prochazkova, M., Kesavapani, S., Amin, N. D., Skulka, V., et al. (2019). Overexpression of the CDK5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model. Hum. Mol. Genet. 28, 3175–3187. doi: 10.1093/hmg/ddz118

Bouhassira, D. (2019). Neuropathic pain: definition, assessment and epidemiology. Rev. Neurol. (Paris) 175, 16–25. doi: 10.1016/j.neurol.2019.08.016

Bowles, K. R., and Jones, L. (2014). Kinase signalling in Huntington’s disease. J. Huntington’s Dis. 3, 89–123. doi: 10.3233/JHD-140106

Brito, V., Girah, A., Masana, M., Royes, A., Espina, M., Suirio, E., et al. (2019). Cyclin-dependent kinase 5 dysfunction contributes to depressive-like behaviors in Huntington’s disease by altering the DARPP-32 phosphorylation status in the nucleus accumbens. Biol. Psychiatry 86, 196–207. doi: 10.1016/j.biopsych.2019.03.001

Chao, A. C., Chen, C. H., Wu, M. H., Hou, B. Y., and Yang, D. I. (2020). Roles of Idd1/HIF-1 and CDK5/HHF-1 in cell cycle reentry induced by amyloid beta peptide in post-mitotic cortical neuron. Biochim. Biophys. Acta Mol. Cell. Res. 1867:118628. doi: 10.1016/j.bbamcr.2019.118628

Chen, H. R., Juan, H. C., Wong, Y. H., Tsai, J. W., and Fann, M. J. (2017). Cdck12 regulates neurogenesis and late-arising neuronal migration in the developing cerebral cortex. Cereb. Cortex 27, 2289–2302. doi: 10.1093/cercor/bhw081

Chen, D., Lan, G., Li, R., Mei, Y., Shui, X., Gu, X., et al. (2022). Melatonin ameliorates tau-related pathology via the mIR-304-3p and CDK5 axis in Alzheimer’s disease. Transl. Neurodegener. 11:27. doi: 10.1186/s40035-022-00302-4

Chen, B., McCuig-Walton, D., Tan, S., Montgomery, A. P., Day, B. W., Kassiou, M., et al. (2021). DRYK1A negatively regulates CDK5-SOX2 pathway and self-renewal of glioblastoma stem cells. Int. J. Mol. Sci. 22:4011. doi: 10.3390/ijms22040411

Chen, C., Peng, X., Tang, J., Hu, Z., Tan, J., and Zeng, L. (2021). CDK5 inhibition protects against OGD induced mitochondrial fragmentation and apoptosis through regulation of Drp15616 phosphorylation. Life Sci. 269:119062. doi: 10.1016/j.lfs.2021.119062

Chen, G., Shan, X., Li, L., Dong, L., Huang, G., and Tao, H. (2022). circHIPK3 regulates apoptosis and mitochondrial dysfunction induced by ischemic stroke in mice by sponging miR-148b-3p via CDKS1/SIRT1. Exp. Neurol. 355:114115. doi: 10.1016/j.expneurol.2022.114115

Chen, X., Yuan, R., Gao, L., Huang, C., Fan, W., Ye, J., et al. (2019). Induction of CRMP-2 phosphorylation by CDK5 restricts the repair of damaged optic nerve. J. Cell. Physiol. 234, 11240–11246. doi: 10.1002/jcp.27778

Cheng, X., Xu, S., Zhang, C., Qin, K., Yan, J., and Shao, X. (2020). The BRCC3 regulated by CDK5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson’s disease models. Biochem. Biophys. Res. Commun. 522, 647–654. doi: 10.1016/j.bbrc.2019.11.141

Chernov, A. V., Remacle, A. G., Hudhugundy, S. K., Casplak, P., Angert, M., Dolkas, J., et al. (2018). Amino acid sequence conservation of the algalic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain. FEBS J. 285, 3485–3502. doi: 10.1111/febs.14625

Cherubini, M., Pugdollibov, M., Albercher, J., and Gines, S. (2015). CDK5-mediated mitochondrial fission: a key player in dopaminergic toxicity in Huntington’s disease. Biochim. Biophys. Acta 1852, 2145–2160. doi: 10.1016/j.bbadis.2015.06.025

Cheung, Z. H., and Ip, N. Y. (2012). CDK5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 22, 169–175. doi: 10.1016/j.tcb.2011.11.003

Ciraku, L., Bacigalupa, Z. A., Ju, J., Moeller, R. A., Le Minh, G., Lee, R. H., et al. (2022). O-GlcNAc transferase regulates glioblastoma acetate metabolism via CDK5 inhibition. J. Cell Sci. 135:202001

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
regulation of CDKs-dependent ACS2 phosphorylation. Oncogene 41, 2122–2136. doi: 10.1038/s41388-022-0233-7

Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D. et al. (2017). Neuropain. Nat. Rev. Dis. Primers 7, 1–20. doi: 10.1038/nrdp.2017.2

Cui, N., Lu, H., Li, M., and Yan, Q. (2017). PTPP21 protects PC12 cell against oxygen-glucose deprivation by activating CDK5 through ERK1/2 signaling pathway. Eur J. Pharmacol. 814, 226–231. doi: 10.1016/j.ejphar.2017.08.021

Daniels, M. H., Malojcic, G., Clagot, S. L., Williams, B., Coeft-He Gal, M., Pan-Zhou, X. R., et al. (2022). Discovery and optimization of highly selective inhibitors of CDKs. J. Med. Chem. 65, 3575–3596. doi: 10.1021/acs.jmedchem.1c02069

Dhavan, R., and Tsai, L. H. (2001). A decade of CDKs. Nat. Rev. Mol. Cell. Biol. 2, 759–775. doi: 10.1038/35060019

Ding, Y., Zhang, L., Zhou, W., Lu, H., Gao, X., Li, J., et al. (2022). Role of cyclin-dependent kinase 5 in early brain injury following experimental subarachnoid hemorrhage. Exp. Ther. Med. 23:147. doi: 10.3892/etm.2021.11070

Dixit, A. B., Banerjee, J., Tripathi, M., Sarkar, C., and Chandra, P. S. (2017). Synaptic role of cyclin-dependent kinase 5 in implications in epilepsy. Indian J. Med. Res. 145, 179–188. doi: 10.4103/ijmr.IJMR_1249_14

Fan, C., Gao, Y., Liang, G., Huang, L., Wang, J., Yang, X., et al. (2020). Transcriptomics of Gabra4 knockout mice reveals common NMDAR pathways underlying autism, memory and epilepsy. Mol. Autism 11:13. doi: 10.1186/s13229-020-0318-9

Fang, B., Zhao, Q., Ling, W., Zhang, Y., and Ou, M. (2019). Hypoxia induces HT-22 neuronal cell death via Orr1/CDK5 pathway-mediated Tau hyperphosphorylation. Am. J. Transl. Res. 11, 5791–7003.

Giannopoulos, P. F., Chiu, J., and Pratico, D. (2019). Learning impairments, memory deficits and neuropathology in aged tau transgenic mice are dependent on leukotrienes biosynthesis: role of the cdk5 kinase pathway. Mol. Neurobiol. 56, 1211–1220. doi: 10.1007/s12053-018-1124-7

Gomez, K., Calderon-Rivera, A., Sandoval, A., Gonzalez-Ramirez, R., Vargas-Parada, A., Oyeda-Alonso, J., et al. (2020a). CDK5-dependent phosphorylation of CaV3.1 t-type channels: possible role in nerve ligation-induced neuroinflammatory allostodyna and the compound action potential in primary afferent C fibers. J. Neurosci. 40, 283–296. doi: 10.1523/JNEUROSCI.0181-19.2019

Gomez, K., Vallecillo, T. G. M., Moutal, A., Perez-Miller, S., Delgado-Lezama, R., Felix, R., et al. (2020b). The role of cyclin-dependent kinase 5 in neuropathic pain. Pain 161, 2674–2689. doi: 10.1097/j.pain.0000000000002027

Gomez, K., Vargas-Parada, A., Duran, P., Sandoval, A., Delgado-Lezama, R., Khanna, R., et al. (2021). L5 spinal nerve ligation-induced neuropathy changes the location and function of Ca2+ channels and CDK5 and affects the compound action potential in adjacent intact L4 afferent fibers. Neuroscience 471, 20–31. doi: 10.1016/j.neuroscience.2021.07.013

Gonzalez-Vera, J. A., Fueyo-Gonzalez, F., Alkorta, I., Peyresasse, M., Morriss, M. C., and Herranz, R. (2016). Highly solvatochromic and tunable fluorophores based on a 4,5-quinolimide scaffold: novel CDK5 probes. Chem. Commun. (Camb) 52, 9625–9625. doi: 10.1039/c4cc4566a

Guo, M. Y., Shang, L., Hu, Y. J., Jiang, L. P., Wan, Y. Y., Zhou, Q. Q., et al. (2018). Role of CDK5-mediated Drp1 phosphorylation in Aβ-42-induced mitochondrial fission and neuronal apoptosis. J. Cell. Biochem. 119, 4815–4825. doi: 10.1002/jcb.26680

Guo, D., Xie, W., Xiong, P., Li, H., Wang, S., Chen, G., et al. (2018). Cyclin-dependent kinase 5-mediated phosphorylation of chloride intracellular channel 4 promotes oxidative stress-induced neuronal death. Cell Death Dis. 9:951. doi: 10.1038/s41419-018-0983-1

Gutierrez-Vargas, J. A., Moreno, H., and Cardona-Gomez, G. P. (2017). Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity. J. Cereb. Blood Flow Metab. 37, 2208–2223. doi: 10.1177/0271678X16662476

He, R., Huang, W., Huang, Y., Xu, M., Song, P., Huang, Y., et al. (2018). CDK5 inhibitory peptide prevents loss of dopaminergic neurons and alleviates behavioral changes in an MPTP induced Parkinson’s disease mouse model. Front. Aging Neurosci. 10. doi: 10.3389/fnagi.2018.00162

He, F., Qi, G., Zhang, Q., Cai, H., Li, T., Li, M., et al. (2020). Quantitative phosphoproteomic analysis in alpha-synuclein transgenic mice reveals the involvement of aberrant p25/CDK5 signaling in early-stage Parkinson’s disease. Cell. Mol. Neurobiol. 40, 897–909. doi: 10.1007/s10571-019-00780-7

Hiragi, T., Ikegaya, Y., and Koyama, R. (2018). Microglia after seizures and in epilepsy. Cells 7:26. doi: 10.3390/cells7040026
Yang, Y. (2018). Oligodendrocyte-specific loss of Cdk5 disrupts the architecture of nodes of Ranvier as well as learning and memory. Exp. Neurol. 306, 92–104. doi: 10.1016/j.expneurol.2018.05.001

Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biol. 15:122. doi: 10.1186/gb1848

Manglani, K., and Dey, C. S. (2022). Cdk5 inhibition improves glucose uptake in insulin-resistant neuronal cells via ERK1/2 pathway. Cell Biol. Int. 46, 488–497. doi: 10.1002/cbin.11735

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of β-amyloid in Alzheimer's disease. Science 330:1774. doi: 10.1126/science.1176233

McColgan, P., and Tahriti, S. J. (2018). Huntington's disease: a clinical review. Eur. J. Neuro. 25, 24–34. doi: 10.1111/eun.14314

Mohamed, N. V., Desjardins, A., and Leclerc, N. (2017). Tau secretion is correlated to an increase of Golgi dynamics. PLoS One 12:e0178288. doi: 10.1371/journal.pone.0178288

Moutal, A., Luo, S., Largent-Milnes, T. M., Vunderer, T. W., and Khanna, R. (2019). Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain. Neurobiol. Pain 5:100022. doi: 10.1016/j.ynyap.2018.07.003

Munoz-Manco, J. J., Gutierrez-Vargas, J. A., and Cardona-Gomez, G. P. (2018). [Neurogenesis and gliogenesis modulation in cerebral ischemia by Cdk5 RNAi-based therapy]. Biomedi. 38, 388–397. doi: 10.7705/biomedica.v38i4.3800

Nie, J., Zhang, Y., Ning, L., Yan, Z., Duan, L., Xi, H., et al. (2022). Phosphorylation of p53 by Cdk5 contributes to benz[a]pyrene-induced neuronal apoptosis. Environ. Toxicol. 25, 1116–1121. doi: 10.1002/tox.23374

Nikhil, K., and Shah, K. (2017). The Cdk5-Med-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer's disease. J. Cell Sci. 130, 3032–3039. doi: 10.1242/jcs.205566

Nikhil, K., Viccaro, K., and Shah, K. (2019). Multifaceted regulation of Aβ degradation by Cdk5 in Alzheimer's disease pathogenesis. Mol. Neurode. 56, 1366–1390. doi: 10.1016/j.mnd.2018.11.014-9

Ning, X., Tao, T., Shen, J., Ji, Y., Xie, L., Wang, H., et al. (2017). The Oc-GlNAC modification of Cdk5 involved in neuronal apoptosis following in vitro intracerebral hemorrhage. Cell. Mol. Neurobiol. 37, 527–536. doi: 10.1007/s10571-017-0383-y

Nishino, H., Saito, T., Wei, R., Takano, T., Totsumi, K., Taniguchi, M., et al. (2019). The LMTK1-TBC1D9B-Rab11A cascade regulates dendritic spine formation via endosome trafficking. J. Neurosci. 39, 9491–9502. doi: 10.1523/JNEUROSCI.3210-18.2019

Ouyang, L., Chen, Y., Wang, Y., Chen, Y., Fu, A. K. Y., Fu, W. Y., et al. (2020). p39-associated Cdk5 activity regulates dendritic morphogenesis. Sci. Rep. 10:18746. doi: 10.1038/s41598-020-75264-6

Palop, J. J., and Mucke, L. (2010). Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812–818. doi: 10.1038/nn.2583

Paolietti, P., Villa, L., Rife, M., Luciano, J. M., Alberich, J., and Gines, S. (2008). Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 28, 10107–10115. doi: 10.1523/JNEUROSCI.0723-08.2008

Pareek, T. K., Lam, E., Zheng, X., Askew, D., Kulkarni, A. B., Chance, M. R., et al. (2010). Cdk5-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 207, 2507–2519. doi: 10.1084/jem.201000876

Park, J., Lee, S., Won, J., Yeo, H. G., Ahn, Y. J., Kim, K., et al. (2019). Abnormal mitochondrial in a non-human primate model of MPTP-induced Parkinson's disease: Drp1 and Cdk5/p25 signaling. Exp. Mol. Med. 51:147262. doi: 10.1016/j.ynapai.2018.07.010

Park, J. W., Won, J., Seo, J., Yeo, H. G., Kim, K., Kim, Y. G., et al. (2020). Streptozotocin induces Alzheimer's disease-like pathology in hippocampal neuronal cells via Cdk5/Drp1-mediated mitochondrial fragmentation. Front. Cell. Neurosci. 14:235. doi: 10.3389/fncel.2020.00235

Peyressetra, M., Arana, D. P., Laure, A., Gonzales-Vera, J. A., Pellerano, M., Masurier, N., et al. (2020a). Identification of quinazoline analogs targeting Cdk5 kinase activity and glioblastoma cell proliferation. Front. Chem. 8:691. doi: 10.3389/fchem.2020.00691

Peyressetra, M., Laure, A., Pellerano, M., Boukhaddouai, H., Soussi, L., and Morris, M. C. (2020b). Fluorescent biosensor of Cdk5 kinase activity in glioblastoma cell extracts and living cells. Biotechnol. J. 15:e1490047. doi: 10.1002/biot.20190474
Poizzo, K., and Bibb, J. A. (2016). The emerging role of CDK5 in cancer. *Trends Cancer* 2, 608–618. doi: 10.1016/j.trecan.2016.09.001

Quo, C., Li, Q. P., Su, Z. R., Ip, S. F., Yuan, Q. J., Xie, Y. L., et al. (2021). Nano-hemoksid ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota. *J. Adv. Res.* 35, 231–243. doi: 10.1016/j.jare.2021.03.012

Quan, Q., Li, X., Feng, J., Hou, J., Li, M., and Zhang, B. (2020). Ginsenoside Rg1 reduces β-amyloid levels by inhibiting CDK5-induced PPARα phosphorylation in a random model of Alzheimer's disease. *Mol. Med. Rep.* 22, 3277–3288. doi: 10.3892/mmr.2020.11424

Quan, Q., Qian, Y., Li, X., and Li, M. (2019). CDK5 participates in amyloid-β production by regulating PPARα phosphorylation in primary rat hippocampal Neurons. *CNS Neurosci. Ther.* 25, 443–460. doi: 10.1111/cns.12945

Shinmyo, Y., Terashibi, Y., Dinh Duong, T. A., Horikke, T., Kawasumi, M., Hosomichi, K., et al. (2017). Blocking of the cerebral cortex requires CDK5 in upper-layer neurons in guineapig mammals. *Cell Rep.* 20, 2131–2143. doi: 10.1016/j.celrep.2017.08.024

Shukla, A. K., Spurrer, J., Kuzina, I., and Giniger, E. (2019). Hyperactive innate immune causes degeneration of dopamine neurons upon altering activity of CDK5. *Cell Rep.* 26, 131–144.e4. doi: 10.1016/j.celrep.2018.12.025

Shukla, R., and Singh, T. R. (2020). Identification of small molecules against cyclin dependent kinase-5 using chemoinformatics approach for Alzheimer's disease and other tauopathies. *J. Biomol. Struct. Dyn.* 40, 2815–2827. doi: 10.1080/07391102.2020.1844050

Shukla, R., and Singh, T. R. (2020). Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease. *J. Biomol. Struct. Dyn.* 38, 248–262. doi: 10.1080/07391102.2019.1571947

Shukla, V., See, J., Binudumur, B. K., Amin, N. D., Reddy, P., Grant, P., et al. (2017). TFP5, a Peptide inhibitor of aberrant and hyperactive CDK5/p25, attenuates pathological phenotypes and restores synaptic function in CK-p25 TG mice. *J. Alzheimers Dis.* 56, 335–349. doi: 10.3233/JAD-160916

Sorensen, H. T. (2019). Global burden of neurological disorders challenges and opportunities with the available data. *Lancet Neurol.* 18, 420–421. doi: 10.1016/S1474-4422(19)30027-4

Spurrer, J., Shukla, A. K., McLinden, K., Johnson, K., and Giniger, E. (2018). Altered expression of the CDK5 activator-like protein, CDKsa, causes neurodegeneration, in part by accelerating the rate of aging. *Dis. Model Mech.* 11:dmm031361. doi: 10.1242/dmm.031361

Stupp, R., Mayer, M., Kann, R., Reder, W., Zouhair, A., Betticher, D. C., et al. (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small cell lung cancer: a multicentre phase II trial. *Lancet Oncol.* 10, 785–793. doi: 10.1016/S1470-2045(09)70172-X

Sun, H., Cai, J., Shen, S., and Ren, X. (2019). Hypothymia treatment ameliorates cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients. *Clinics (Sao Paulo)* 74:6958. doi: 10.6061/clinics/2019/e938

Tabouret, E., Wang, H., Amin, N., Jung, J., Appay, R., Cai, J., et al. (2020). TPS, a peptide inhibitor of aberrant and hyperactive CDK5/p25, a novel therapeutic approach against glioblastoma. *J. Neurooncol.* 145, 1239–1250. doi: 10.1007/s11060-019-03431-6

Takahashi, M., Nakaibayashi, T., Mitra, N., Jin, X., Aikawa, Y., Sasamoto, K., et al. (2022a). Involvement of Cdk5 activating subunit p35 in synaptic plasticity in excitatory and inhibitory neurons. *Mol. Brain* 15:37. doi: 10.1186/s13041-022-00822-y

Takahashi, M., Takaguti, T., Kawakami, A., Wei, R., Ando, K., Ohshima, T., et al. (2022b). Valproic acid-induced anxiety and depression behaviors are ameliorated in p39 CDK5 activator-deficient mice. *Neurochem. Res.* doi: 10.1007/s11064-022-03642-9. [Online ahead of print].

Tanaka, T., Ohashi, S., Takahisa, A., and Kobayashi, S. (2022). Dendritic distribution of CDK5 mRNAs and p35 mRNA and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hyperphosphorylation. *Biochim. Biophys. Acta Gen. Subj.* 1866:130135. doi: 10.1016/j.bbagrm.2022.130135

Tejero, R., Balc, S., Franco-Espin, J., Oreda, J., Hennell, L., Drexl, H., et al. (2020). R-roscovinine improves motoneuron function in mouse models for spinal muscular atrophy. *Acta Gen. Subj.* 15:37. doi: 10.1016/j.actgen.2020.11001-2

Thujs, R. D., Surges, R., O'Brien, T. J., and Sander, J. W. (2019). Epilepsy in adults. *Lancet* 393, 689–701. doi: 10.1016/S0140-6736(18)32596-0

 Tian, F. F., Guo, T. H., and Chen, J. M. (2008). [Hippocampal mossy fiber sprouting and Cdk5/p35 expressions in the pentyleneetetrazole kindling rat model]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 33, 1101–1107

Tian, F.-F., Zeng, C., Ma, Y. F., Guo, T.-H., Chen, J. M., Chen, Y. et al. (2010). Potential roles of CDK5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model. *Clin. Neurol. 56, 127–136.*
Efector action of estrogen on tau phosphorylation via CDK5 signal transduction

Estrogen improved the regeneration of axons after subcortical axon injury via roscovitine alleviates neuropathic pain in the dorsal root ganglia by Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease.